nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP3A5—prostate cancer	0.153	0.417	CbGaD
Nevirapine—CYP2A6—prostate cancer	0.148	0.403	CbGaD
Nevirapine—CYP3A4—prostate cancer	0.0663	0.18	CbGaD
Nevirapine—CYP3A5—Flutamide—prostate cancer	0.0252	0.0623	CbGbCtD
Nevirapine—CYP2B6—Estrone—prostate cancer	0.0231	0.0572	CbGbCtD
Nevirapine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0226	0.0558	CbGbCtD
Nevirapine—CYP2B6—Ethinyl Estradiol—prostate cancer	0.0206	0.0509	CbGbCtD
Nevirapine—CYP2C9—Bicalutamide—prostate cancer	0.0204	0.0504	CbGbCtD
Nevirapine—CYP2C9—Nilutamide—prostate cancer	0.0204	0.0504	CbGbCtD
Nevirapine—CYP1A2—Flutamide—prostate cancer	0.0188	0.0463	CbGbCtD
Nevirapine—CYP2D6—Bicalutamide—prostate cancer	0.0187	0.0461	CbGbCtD
Nevirapine—CYP3A5—Cabazitaxel—prostate cancer	0.0187	0.0461	CbGbCtD
Nevirapine—CYP3A5—Estrone—prostate cancer	0.0182	0.045	CbGbCtD
Nevirapine—CYP2D6—Abiraterone—prostate cancer	0.0155	0.0382	CbGbCtD
Nevirapine—CYP1A2—Estrone—prostate cancer	0.0136	0.0335	CbGbCtD
Nevirapine—CYP2C9—Estrone—prostate cancer	0.0122	0.0302	CbGbCtD
Nevirapine—CYP3A4—Bicalutamide—prostate cancer	0.0119	0.0293	CbGbCtD
Nevirapine—CYP3A4—Estramustine—prostate cancer	0.011	0.0272	CbGbCtD
Nevirapine—CYP3A5—Estradiol—prostate cancer	0.0105	0.0259	CbGbCtD
Nevirapine—CYP3A4—Abiraterone—prostate cancer	0.00983	0.0243	CbGbCtD
Nevirapine—CYP3A4—Flutamide—prostate cancer	0.00983	0.0243	CbGbCtD
Nevirapine—CYP2C9—Capecitabine—prostate cancer	0.00927	0.0229	CbGbCtD
Nevirapine—CYP1A2—Conjugated Estrogens—prostate cancer	0.00888	0.0219	CbGbCtD
Nevirapine—CYP1A2—Estradiol—prostate cancer	0.00779	0.0192	CbGbCtD
Nevirapine—CYP3A4—Cabazitaxel—prostate cancer	0.00727	0.018	CbGbCtD
Nevirapine—CYP3A4—Estrone—prostate cancer	0.00711	0.0176	CbGbCtD
Nevirapine—CYP2C9—Estradiol—prostate cancer	0.00702	0.0173	CbGbCtD
Nevirapine—CYP3A5—Etoposide—prostate cancer	0.00684	0.0169	CbGbCtD
Nevirapine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00634	0.0156	CbGbCtD
Nevirapine—CYP3A5—Docetaxel—prostate cancer	0.00626	0.0154	CbGbCtD
Nevirapine—CYP2B6—Doxorubicin—prostate cancer	0.00592	0.0146	CbGbCtD
Nevirapine—CYP1A2—Etoposide—prostate cancer	0.00509	0.0126	CbGbCtD
Nevirapine—CYP3A4—Conjugated Estrogens—prostate cancer	0.00465	0.0115	CbGbCtD
Nevirapine—CYP3A4—Mitoxantrone—prostate cancer	0.00423	0.0104	CbGbCtD
Nevirapine—CYP3A4—Estradiol—prostate cancer	0.00408	0.0101	CbGbCtD
Nevirapine—CYP3A4—Prednisone—prostate cancer	0.00351	0.00867	CbGbCtD
Nevirapine—CYP2D6—Doxorubicin—prostate cancer	0.00286	0.00706	CbGbCtD
Nevirapine—CYP3A4—Etoposide—prostate cancer	0.00267	0.00658	CbGbCtD
Nevirapine—CYP3A4—Docetaxel—prostate cancer	0.00244	0.00602	CbGbCtD
Nevirapine—CYP3A4—Doxorubicin—prostate cancer	0.00182	0.00449	CbGbCtD
Nevirapine—CYP1A2—urine—prostate cancer	0.000871	0.158	CbGeAlD
Nevirapine—CYP2C9—urine—prostate cancer	0.000827	0.15	CbGeAlD
Nevirapine—CYP3A4—urine—prostate cancer	0.00063	0.114	CbGeAlD
Nevirapine—CYP2D6—urine—prostate cancer	0.00062	0.113	CbGeAlD
Nevirapine—CYP2A6—prostate gland—prostate cancer	0.000595	0.108	CbGeAlD
Nevirapine—CYP2A6—seminal vesicle—prostate cancer	0.000503	0.0914	CbGeAlD
Nevirapine—CYP3A5—prostate gland—prostate cancer	0.000301	0.0547	CbGeAlD
Nevirapine—CYP1A2—renal system—prostate cancer	0.000213	0.0387	CbGeAlD
Nevirapine—CYP3A5—renal system—prostate cancer	0.000205	0.0373	CbGeAlD
Nevirapine—CYP2B6—renal system—prostate cancer	0.000204	0.0371	CbGeAlD
Nevirapine—CYP3A4—renal system—prostate cancer	0.000154	0.028	CbGeAlD
Nevirapine—CYP2D6—renal system—prostate cancer	0.000152	0.0276	CbGeAlD
Nevirapine—CYP2B6—testis—prostate cancer	0.000132	0.024	CbGeAlD
Nevirapine—CYP2D6—testis—prostate cancer	9.81e-05	0.0178	CbGeAlD
Nevirapine—Alanine aminotransferase increased—Epirubicin—prostate cancer	6.12e-05	0.000462	CcSEcCtD
Nevirapine—Anaphylactic shock—Etoposide—prostate cancer	6.08e-05	0.000459	CcSEcCtD
Nevirapine—Connective tissue disorder—Prednisone—prostate cancer	6.03e-05	0.000455	CcSEcCtD
Nevirapine—Feeling abnormal—Mitoxantrone—prostate cancer	6.02e-05	0.000455	CcSEcCtD
Nevirapine—Erythema—Capecitabine—prostate cancer	5.99e-05	0.000452	CcSEcCtD
Nevirapine—Gastrointestinal pain—Mitoxantrone—prostate cancer	5.98e-05	0.000451	CcSEcCtD
Nevirapine—Thrombocytopenia—Etoposide—prostate cancer	5.95e-05	0.000449	CcSEcCtD
Nevirapine—Eosinophilia—Epirubicin—prostate cancer	5.93e-05	0.000448	CcSEcCtD
Nevirapine—Liver function test abnormal—Doxorubicin—prostate cancer	5.92e-05	0.000447	CcSEcCtD
Nevirapine—Skin disorder—Etoposide—prostate cancer	5.91e-05	0.000446	CcSEcCtD
Nevirapine—Nausea—Goserelin—prostate cancer	5.88e-05	0.000444	CcSEcCtD
Nevirapine—Pancreatitis—Epirubicin—prostate cancer	5.88e-05	0.000444	CcSEcCtD
Nevirapine—Nausea—Conjugated Estrogens—prostate cancer	5.82e-05	0.000439	CcSEcCtD
Nevirapine—Urticaria—Mitoxantrone—prostate cancer	5.81e-05	0.000438	CcSEcCtD
Nevirapine—Anorexia—Etoposide—prostate cancer	5.8e-05	0.000437	CcSEcCtD
Nevirapine—Hypersensitivity—Estradiol—prostate cancer	5.78e-05	0.000436	CcSEcCtD
Nevirapine—Abdominal pain—Mitoxantrone—prostate cancer	5.78e-05	0.000436	CcSEcCtD
Nevirapine—Body temperature increased—Mitoxantrone—prostate cancer	5.78e-05	0.000436	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	5.78e-05	0.000436	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	5.78e-05	0.000436	CcSEcCtD
Nevirapine—Anaemia—Docetaxel—prostate cancer	5.72e-05	0.000432	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Doxorubicin—prostate cancer	5.66e-05	0.000427	CcSEcCtD
Nevirapine—Asthenia—Estradiol—prostate cancer	5.63e-05	0.000425	CcSEcCtD
Nevirapine—Neutropenia—Epirubicin—prostate cancer	5.6e-05	0.000423	CcSEcCtD
Nevirapine—Ill-defined disorder—Capecitabine—prostate cancer	5.56e-05	0.00042	CcSEcCtD
Nevirapine—Pruritus—Estradiol—prostate cancer	5.55e-05	0.000419	CcSEcCtD
Nevirapine—Anaemia—Capecitabine—prostate cancer	5.54e-05	0.000418	CcSEcCtD
Nevirapine—Immune system disorder—Prednisone—prostate cancer	5.54e-05	0.000418	CcSEcCtD
Nevirapine—Eosinophilia—Doxorubicin—prostate cancer	5.49e-05	0.000414	CcSEcCtD
Nevirapine—Paraesthesia—Etoposide—prostate cancer	5.46e-05	0.000412	CcSEcCtD
Nevirapine—Pancreatitis—Doxorubicin—prostate cancer	5.44e-05	0.00041	CcSEcCtD
Nevirapine—Hyperglycaemia—Epirubicin—prostate cancer	5.41e-05	0.000408	CcSEcCtD
Nevirapine—Malaise—Capecitabine—prostate cancer	5.41e-05	0.000408	CcSEcCtD
Nevirapine—Somnolence—Etoposide—prostate cancer	5.41e-05	0.000408	CcSEcCtD
Nevirapine—Hypersensitivity—Mitoxantrone—prostate cancer	5.39e-05	0.000407	CcSEcCtD
Nevirapine—Diarrhoea—Estradiol—prostate cancer	5.37e-05	0.000405	CcSEcCtD
Nevirapine—Erythema—Prednisone—prostate cancer	5.34e-05	0.000403	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Epirubicin—prostate cancer	5.3e-05	0.0004	CcSEcCtD
Nevirapine—Decreased appetite—Etoposide—prostate cancer	5.29e-05	0.000399	CcSEcCtD
Nevirapine—Arthralgia—Docetaxel—prostate cancer	5.27e-05	0.000398	CcSEcCtD
Nevirapine—Myalgia—Docetaxel—prostate cancer	5.27e-05	0.000398	CcSEcCtD
Nevirapine—Renal failure—Epirubicin—prostate cancer	5.25e-05	0.000397	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Etoposide—prostate cancer	5.25e-05	0.000396	CcSEcCtD
Nevirapine—Asthenia—Mitoxantrone—prostate cancer	5.24e-05	0.000396	CcSEcCtD
Nevirapine—Fatigue—Etoposide—prostate cancer	5.24e-05	0.000396	CcSEcCtD
Nevirapine—Neuropathy peripheral—Epirubicin—prostate cancer	5.24e-05	0.000395	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	5.24e-05	0.000395	CcSEcCtD
Nevirapine—Jaundice—Epirubicin—prostate cancer	5.21e-05	0.000393	CcSEcCtD
Nevirapine—Pain—Etoposide—prostate cancer	5.2e-05	0.000392	CcSEcCtD
Nevirapine—Conjunctivitis—Epirubicin—prostate cancer	5.19e-05	0.000392	CcSEcCtD
Nevirapine—Neutropenia—Doxorubicin—prostate cancer	5.19e-05	0.000391	CcSEcCtD
Nevirapine—Myalgia—Capecitabine—prostate cancer	5.1e-05	0.000385	CcSEcCtD
Nevirapine—Arthralgia—Capecitabine—prostate cancer	5.1e-05	0.000385	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	5.07e-05	0.000383	CcSEcCtD
Nevirapine—Hepatobiliary disease—Epirubicin—prostate cancer	5.05e-05	0.000381	CcSEcCtD
Nevirapine—Anaphylactic shock—Docetaxel—prostate cancer	5.05e-05	0.000381	CcSEcCtD
Nevirapine—Oedema—Docetaxel—prostate cancer	5.05e-05	0.000381	CcSEcCtD
Nevirapine—Discomfort—Capecitabine—prostate cancer	5.04e-05	0.000381	CcSEcCtD
Nevirapine—Feeling abnormal—Etoposide—prostate cancer	5.01e-05	0.000378	CcSEcCtD
Nevirapine—Hyperglycaemia—Doxorubicin—prostate cancer	5e-05	0.000378	CcSEcCtD
Nevirapine—Diarrhoea—Mitoxantrone—prostate cancer	5e-05	0.000378	CcSEcCtD
Nevirapine—Vomiting—Estradiol—prostate cancer	4.99e-05	0.000376	CcSEcCtD
Nevirapine—Agranulocytosis—Epirubicin—prostate cancer	4.99e-05	0.000376	CcSEcCtD
Nevirapine—Gastrointestinal pain—Etoposide—prostate cancer	4.97e-05	0.000375	CcSEcCtD
Nevirapine—Nervous system disorder—Docetaxel—prostate cancer	4.96e-05	0.000374	CcSEcCtD
Nevirapine—Ill-defined disorder—Prednisone—prostate cancer	4.95e-05	0.000374	CcSEcCtD
Nevirapine—Thrombocytopenia—Docetaxel—prostate cancer	4.95e-05	0.000373	CcSEcCtD
Nevirapine—Rash—Estradiol—prostate cancer	4.95e-05	0.000373	CcSEcCtD
Nevirapine—Dermatitis—Estradiol—prostate cancer	4.94e-05	0.000373	CcSEcCtD
Nevirapine—Anaemia—Prednisone—prostate cancer	4.94e-05	0.000373	CcSEcCtD
Nevirapine—Headache—Estradiol—prostate cancer	4.91e-05	0.000371	CcSEcCtD
Nevirapine—Skin disorder—Docetaxel—prostate cancer	4.91e-05	0.00037	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	4.9e-05	0.00037	CcSEcCtD
Nevirapine—Oedema—Capecitabine—prostate cancer	4.89e-05	0.000369	CcSEcCtD
Nevirapine—Angioedema—Prednisone—prostate cancer	4.88e-05	0.000368	CcSEcCtD
Nevirapine—Renal failure—Doxorubicin—prostate cancer	4.86e-05	0.000367	CcSEcCtD
Nevirapine—Neuropathy peripheral—Doxorubicin—prostate cancer	4.85e-05	0.000366	CcSEcCtD
Nevirapine—Urticaria—Etoposide—prostate cancer	4.83e-05	0.000365	CcSEcCtD
Nevirapine—Jaundice—Doxorubicin—prostate cancer	4.82e-05	0.000364	CcSEcCtD
Nevirapine—Anorexia—Docetaxel—prostate cancer	4.82e-05	0.000364	CcSEcCtD
Nevirapine—Malaise—Prednisone—prostate cancer	4.82e-05	0.000363	CcSEcCtD
Nevirapine—Abdominal pain—Etoposide—prostate cancer	4.81e-05	0.000363	CcSEcCtD
Nevirapine—Body temperature increased—Etoposide—prostate cancer	4.81e-05	0.000363	CcSEcCtD
Nevirapine—Conjunctivitis—Doxorubicin—prostate cancer	4.81e-05	0.000363	CcSEcCtD
Nevirapine—Nervous system disorder—Capecitabine—prostate cancer	4.8e-05	0.000362	CcSEcCtD
Nevirapine—Hepatitis—Epirubicin—prostate cancer	4.8e-05	0.000362	CcSEcCtD
Nevirapine—Thrombocytopenia—Capecitabine—prostate cancer	4.79e-05	0.000362	CcSEcCtD
Nevirapine—Skin disorder—Capecitabine—prostate cancer	4.75e-05	0.000359	CcSEcCtD
Nevirapine—Connective tissue disorder—Epirubicin—prostate cancer	4.71e-05	0.000356	CcSEcCtD
Nevirapine—Hepatobiliary disease—Doxorubicin—prostate cancer	4.68e-05	0.000353	CcSEcCtD
Nevirapine—Anorexia—Capecitabine—prostate cancer	4.66e-05	0.000352	CcSEcCtD
Nevirapine—Nausea—Estradiol—prostate cancer	4.66e-05	0.000352	CcSEcCtD
Nevirapine—Vomiting—Mitoxantrone—prostate cancer	4.65e-05	0.000351	CcSEcCtD
Nevirapine—Agranulocytosis—Doxorubicin—prostate cancer	4.61e-05	0.000348	CcSEcCtD
Nevirapine—Rash—Mitoxantrone—prostate cancer	4.61e-05	0.000348	CcSEcCtD
Nevirapine—Dermatitis—Mitoxantrone—prostate cancer	4.6e-05	0.000348	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.6e-05	0.000347	CcSEcCtD
Nevirapine—Headache—Mitoxantrone—prostate cancer	4.58e-05	0.000346	CcSEcCtD
Nevirapine—Arthralgia—Prednisone—prostate cancer	4.55e-05	0.000343	CcSEcCtD
Nevirapine—Myalgia—Prednisone—prostate cancer	4.55e-05	0.000343	CcSEcCtD
Nevirapine—Paraesthesia—Docetaxel—prostate cancer	4.54e-05	0.000342	CcSEcCtD
Nevirapine—Erythema multiforme—Epirubicin—prostate cancer	4.54e-05	0.000342	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.51e-05	0.000341	CcSEcCtD
Nevirapine—Somnolence—Docetaxel—prostate cancer	4.49e-05	0.000339	CcSEcCtD
Nevirapine—Discomfort—Prednisone—prostate cancer	4.49e-05	0.000339	CcSEcCtD
Nevirapine—Hypersensitivity—Etoposide—prostate cancer	4.48e-05	0.000338	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.46e-05	0.000336	CcSEcCtD
Nevirapine—Hepatitis—Doxorubicin—prostate cancer	4.44e-05	0.000335	CcSEcCtD
Nevirapine—Paraesthesia—Capecitabine—prostate cancer	4.39e-05	0.000332	CcSEcCtD
Nevirapine—Decreased appetite—Docetaxel—prostate cancer	4.39e-05	0.000332	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Docetaxel—prostate cancer	4.36e-05	0.000329	CcSEcCtD
Nevirapine—Asthenia—Etoposide—prostate cancer	4.36e-05	0.000329	CcSEcCtD
Nevirapine—Connective tissue disorder—Doxorubicin—prostate cancer	4.36e-05	0.000329	CcSEcCtD
Nevirapine—Oedema—Prednisone—prostate cancer	4.36e-05	0.000329	CcSEcCtD
Nevirapine—Anaphylactic shock—Prednisone—prostate cancer	4.36e-05	0.000329	CcSEcCtD
Nevirapine—Fatigue—Docetaxel—prostate cancer	4.36e-05	0.000329	CcSEcCtD
Nevirapine—Nausea—Mitoxantrone—prostate cancer	4.34e-05	0.000328	CcSEcCtD
Nevirapine—Immune system disorder—Epirubicin—prostate cancer	4.33e-05	0.000327	CcSEcCtD
Nevirapine—Pain—Docetaxel—prostate cancer	4.32e-05	0.000326	CcSEcCtD
Nevirapine—Pruritus—Etoposide—prostate cancer	4.3e-05	0.000325	CcSEcCtD
Nevirapine—Nervous system disorder—Prednisone—prostate cancer	4.27e-05	0.000323	CcSEcCtD
Nevirapine—Decreased appetite—Capecitabine—prostate cancer	4.25e-05	0.000321	CcSEcCtD
Nevirapine—Skin disorder—Prednisone—prostate cancer	4.23e-05	0.000319	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Capecitabine—prostate cancer	4.22e-05	0.000319	CcSEcCtD
Nevirapine—Fatigue—Capecitabine—prostate cancer	4.22e-05	0.000318	CcSEcCtD
Nevirapine—Erythema multiforme—Doxorubicin—prostate cancer	4.2e-05	0.000317	CcSEcCtD
Nevirapine—Pain—Capecitabine—prostate cancer	4.18e-05	0.000316	CcSEcCtD
Nevirapine—Erythema—Epirubicin—prostate cancer	4.18e-05	0.000315	CcSEcCtD
Nevirapine—Feeling abnormal—Docetaxel—prostate cancer	4.16e-05	0.000314	CcSEcCtD
Nevirapine—Diarrhoea—Etoposide—prostate cancer	4.16e-05	0.000314	CcSEcCtD
Nevirapine—Anorexia—Prednisone—prostate cancer	4.15e-05	0.000314	CcSEcCtD
Nevirapine—Gastrointestinal pain—Docetaxel—prostate cancer	4.13e-05	0.000312	CcSEcCtD
Nevirapine—Feeling abnormal—Capecitabine—prostate cancer	4.03e-05	0.000304	CcSEcCtD
Nevirapine—Immune system disorder—Doxorubicin—prostate cancer	4.01e-05	0.000303	CcSEcCtD
Nevirapine—Gastrointestinal pain—Capecitabine—prostate cancer	4e-05	0.000302	CcSEcCtD
Nevirapine—Abdominal pain—Docetaxel—prostate cancer	3.99e-05	0.000302	CcSEcCtD
Nevirapine—Body temperature increased—Docetaxel—prostate cancer	3.99e-05	0.000302	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Prednisone—prostate cancer	3.97e-05	0.0003	CcSEcCtD
Nevirapine—Paraesthesia—Prednisone—prostate cancer	3.91e-05	0.000295	CcSEcCtD
Nevirapine—Urticaria—Capecitabine—prostate cancer	3.89e-05	0.000293	CcSEcCtD
Nevirapine—Ill-defined disorder—Epirubicin—prostate cancer	3.87e-05	0.000292	CcSEcCtD
Nevirapine—Abdominal pain—Capecitabine—prostate cancer	3.87e-05	0.000292	CcSEcCtD
Nevirapine—Body temperature increased—Capecitabine—prostate cancer	3.87e-05	0.000292	CcSEcCtD
Nevirapine—Vomiting—Etoposide—prostate cancer	3.87e-05	0.000292	CcSEcCtD
Nevirapine—Erythema—Doxorubicin—prostate cancer	3.86e-05	0.000292	CcSEcCtD
Nevirapine—Anaemia—Epirubicin—prostate cancer	3.86e-05	0.000291	CcSEcCtD
Nevirapine—Rash—Etoposide—prostate cancer	3.83e-05	0.000289	CcSEcCtD
Nevirapine—Dermatitis—Etoposide—prostate cancer	3.83e-05	0.000289	CcSEcCtD
Nevirapine—Headache—Etoposide—prostate cancer	3.81e-05	0.000288	CcSEcCtD
Nevirapine—Decreased appetite—Prednisone—prostate cancer	3.79e-05	0.000286	CcSEcCtD
Nevirapine—Malaise—Epirubicin—prostate cancer	3.77e-05	0.000284	CcSEcCtD
Nevirapine—Fatigue—Prednisone—prostate cancer	3.76e-05	0.000284	CcSEcCtD
Nevirapine—Hypersensitivity—Docetaxel—prostate cancer	3.72e-05	0.000281	CcSEcCtD
Nevirapine—Asthenia—Docetaxel—prostate cancer	3.63e-05	0.000274	CcSEcCtD
Nevirapine—Nausea—Etoposide—prostate cancer	3.61e-05	0.000273	CcSEcCtD
Nevirapine—Hypersensitivity—Capecitabine—prostate cancer	3.6e-05	0.000272	CcSEcCtD
Nevirapine—Feeling abnormal—Prednisone—prostate cancer	3.59e-05	0.000271	CcSEcCtD
Nevirapine—Ill-defined disorder—Doxorubicin—prostate cancer	3.59e-05	0.000271	CcSEcCtD
Nevirapine—Pruritus—Docetaxel—prostate cancer	3.58e-05	0.00027	CcSEcCtD
Nevirapine—Anaemia—Doxorubicin—prostate cancer	3.57e-05	0.00027	CcSEcCtD
Nevirapine—Gastrointestinal pain—Prednisone—prostate cancer	3.56e-05	0.000269	CcSEcCtD
Nevirapine—Myalgia—Epirubicin—prostate cancer	3.56e-05	0.000268	CcSEcCtD
Nevirapine—Arthralgia—Epirubicin—prostate cancer	3.56e-05	0.000268	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.53e-05	0.000267	CcSEcCtD
Nevirapine—Discomfort—Epirubicin—prostate cancer	3.51e-05	0.000265	CcSEcCtD
Nevirapine—Asthenia—Capecitabine—prostate cancer	3.51e-05	0.000265	CcSEcCtD
Nevirapine—Malaise—Doxorubicin—prostate cancer	3.48e-05	0.000263	CcSEcCtD
Nevirapine—Urticaria—Prednisone—prostate cancer	3.46e-05	0.000261	CcSEcCtD
Nevirapine—Pruritus—Capecitabine—prostate cancer	3.46e-05	0.000261	CcSEcCtD
Nevirapine—Diarrhoea—Docetaxel—prostate cancer	3.46e-05	0.000261	CcSEcCtD
Nevirapine—Abdominal pain—Prednisone—prostate cancer	3.45e-05	0.00026	CcSEcCtD
Nevirapine—Body temperature increased—Prednisone—prostate cancer	3.45e-05	0.00026	CcSEcCtD
Nevirapine—Anaphylactic shock—Epirubicin—prostate cancer	3.41e-05	0.000257	CcSEcCtD
Nevirapine—Oedema—Epirubicin—prostate cancer	3.41e-05	0.000257	CcSEcCtD
Nevirapine—Diarrhoea—Capecitabine—prostate cancer	3.35e-05	0.000253	CcSEcCtD
Nevirapine—Nervous system disorder—Epirubicin—prostate cancer	3.34e-05	0.000252	CcSEcCtD
Nevirapine—Thrombocytopenia—Epirubicin—prostate cancer	3.34e-05	0.000252	CcSEcCtD
Nevirapine—Skin disorder—Epirubicin—prostate cancer	3.31e-05	0.00025	CcSEcCtD
Nevirapine—Arthralgia—Doxorubicin—prostate cancer	3.29e-05	0.000248	CcSEcCtD
Nevirapine—Myalgia—Doxorubicin—prostate cancer	3.29e-05	0.000248	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.27e-05	0.000247	CcSEcCtD
Nevirapine—Discomfort—Doxorubicin—prostate cancer	3.25e-05	0.000245	CcSEcCtD
Nevirapine—Anorexia—Epirubicin—prostate cancer	3.25e-05	0.000245	CcSEcCtD
Nevirapine—Vomiting—Docetaxel—prostate cancer	3.21e-05	0.000243	CcSEcCtD
Nevirapine—Hypersensitivity—Prednisone—prostate cancer	3.21e-05	0.000242	CcSEcCtD
Nevirapine—Rash—Docetaxel—prostate cancer	3.19e-05	0.00024	CcSEcCtD
Nevirapine—Dermatitis—Docetaxel—prostate cancer	3.18e-05	0.00024	CcSEcCtD
Nevirapine—Headache—Docetaxel—prostate cancer	3.17e-05	0.000239	CcSEcCtD
Nevirapine—Oedema—Doxorubicin—prostate cancer	3.15e-05	0.000238	CcSEcCtD
Nevirapine—Anaphylactic shock—Doxorubicin—prostate cancer	3.15e-05	0.000238	CcSEcCtD
Nevirapine—Asthenia—Prednisone—prostate cancer	3.13e-05	0.000236	CcSEcCtD
Nevirapine—Vomiting—Capecitabine—prostate cancer	3.11e-05	0.000235	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Epirubicin—prostate cancer	3.11e-05	0.000234	CcSEcCtD
Nevirapine—Nervous system disorder—Doxorubicin—prostate cancer	3.09e-05	0.000233	CcSEcCtD
Nevirapine—Thrombocytopenia—Doxorubicin—prostate cancer	3.09e-05	0.000233	CcSEcCtD
Nevirapine—Rash—Capecitabine—prostate cancer	3.08e-05	0.000233	CcSEcCtD
Nevirapine—Pruritus—Prednisone—prostate cancer	3.08e-05	0.000233	CcSEcCtD
Nevirapine—Dermatitis—Capecitabine—prostate cancer	3.08e-05	0.000233	CcSEcCtD
Nevirapine—Headache—Capecitabine—prostate cancer	3.06e-05	0.000231	CcSEcCtD
Nevirapine—Skin disorder—Doxorubicin—prostate cancer	3.06e-05	0.000231	CcSEcCtD
Nevirapine—Paraesthesia—Epirubicin—prostate cancer	3.06e-05	0.000231	CcSEcCtD
Nevirapine—Somnolence—Epirubicin—prostate cancer	3.03e-05	0.000229	CcSEcCtD
Nevirapine—Anorexia—Doxorubicin—prostate cancer	3.01e-05	0.000227	CcSEcCtD
Nevirapine—Nausea—Docetaxel—prostate cancer	3e-05	0.000227	CcSEcCtD
Nevirapine—Diarrhoea—Prednisone—prostate cancer	2.98e-05	0.000225	CcSEcCtD
Nevirapine—Decreased appetite—Epirubicin—prostate cancer	2.96e-05	0.000224	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Epirubicin—prostate cancer	2.94e-05	0.000222	CcSEcCtD
Nevirapine—Fatigue—Epirubicin—prostate cancer	2.94e-05	0.000222	CcSEcCtD
Nevirapine—Pain—Epirubicin—prostate cancer	2.91e-05	0.00022	CcSEcCtD
Nevirapine—Nausea—Capecitabine—prostate cancer	2.91e-05	0.000219	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.87e-05	0.000217	CcSEcCtD
Nevirapine—Paraesthesia—Doxorubicin—prostate cancer	2.83e-05	0.000214	CcSEcCtD
Nevirapine—Feeling abnormal—Epirubicin—prostate cancer	2.81e-05	0.000212	CcSEcCtD
Nevirapine—Somnolence—Doxorubicin—prostate cancer	2.8e-05	0.000212	CcSEcCtD
Nevirapine—Gastrointestinal pain—Epirubicin—prostate cancer	2.79e-05	0.00021	CcSEcCtD
Nevirapine—Vomiting—Prednisone—prostate cancer	2.77e-05	0.000209	CcSEcCtD
Nevirapine—Rash—Prednisone—prostate cancer	2.75e-05	0.000207	CcSEcCtD
Nevirapine—Dermatitis—Prednisone—prostate cancer	2.75e-05	0.000207	CcSEcCtD
Nevirapine—Decreased appetite—Doxorubicin—prostate cancer	2.74e-05	0.000207	CcSEcCtD
Nevirapine—Headache—Prednisone—prostate cancer	2.73e-05	0.000206	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.72e-05	0.000206	CcSEcCtD
Nevirapine—Fatigue—Doxorubicin—prostate cancer	2.72e-05	0.000205	CcSEcCtD
Nevirapine—Urticaria—Epirubicin—prostate cancer	2.71e-05	0.000204	CcSEcCtD
Nevirapine—Pain—Doxorubicin—prostate cancer	2.7e-05	0.000204	CcSEcCtD
Nevirapine—Body temperature increased—Epirubicin—prostate cancer	2.69e-05	0.000203	CcSEcCtD
Nevirapine—Abdominal pain—Epirubicin—prostate cancer	2.69e-05	0.000203	CcSEcCtD
Nevirapine—Feeling abnormal—Doxorubicin—prostate cancer	2.6e-05	0.000196	CcSEcCtD
Nevirapine—Nausea—Prednisone—prostate cancer	2.59e-05	0.000195	CcSEcCtD
Nevirapine—Gastrointestinal pain—Doxorubicin—prostate cancer	2.58e-05	0.000195	CcSEcCtD
Nevirapine—Hypersensitivity—Epirubicin—prostate cancer	2.51e-05	0.00019	CcSEcCtD
Nevirapine—Urticaria—Doxorubicin—prostate cancer	2.51e-05	0.000189	CcSEcCtD
Nevirapine—Body temperature increased—Doxorubicin—prostate cancer	2.49e-05	0.000188	CcSEcCtD
Nevirapine—Abdominal pain—Doxorubicin—prostate cancer	2.49e-05	0.000188	CcSEcCtD
Nevirapine—Asthenia—Epirubicin—prostate cancer	2.45e-05	0.000185	CcSEcCtD
Nevirapine—Pruritus—Epirubicin—prostate cancer	2.41e-05	0.000182	CcSEcCtD
Nevirapine—Diarrhoea—Epirubicin—prostate cancer	2.33e-05	0.000176	CcSEcCtD
Nevirapine—Hypersensitivity—Doxorubicin—prostate cancer	2.32e-05	0.000175	CcSEcCtD
Nevirapine—Asthenia—Doxorubicin—prostate cancer	2.26e-05	0.000171	CcSEcCtD
Nevirapine—Pruritus—Doxorubicin—prostate cancer	2.23e-05	0.000168	CcSEcCtD
Nevirapine—Vomiting—Epirubicin—prostate cancer	2.17e-05	0.000164	CcSEcCtD
Nevirapine—Diarrhoea—Doxorubicin—prostate cancer	2.16e-05	0.000163	CcSEcCtD
Nevirapine—Rash—Epirubicin—prostate cancer	2.15e-05	0.000162	CcSEcCtD
Nevirapine—Dermatitis—Epirubicin—prostate cancer	2.15e-05	0.000162	CcSEcCtD
Nevirapine—Headache—Epirubicin—prostate cancer	2.14e-05	0.000161	CcSEcCtD
Nevirapine—Nausea—Epirubicin—prostate cancer	2.02e-05	0.000153	CcSEcCtD
Nevirapine—Vomiting—Doxorubicin—prostate cancer	2.01e-05	0.000151	CcSEcCtD
Nevirapine—Rash—Doxorubicin—prostate cancer	1.99e-05	0.00015	CcSEcCtD
Nevirapine—Dermatitis—Doxorubicin—prostate cancer	1.99e-05	0.00015	CcSEcCtD
Nevirapine—Headache—Doxorubicin—prostate cancer	1.98e-05	0.000149	CcSEcCtD
Nevirapine—Nausea—Doxorubicin—prostate cancer	1.87e-05	0.000141	CcSEcCtD
Nevirapine—CYP2D6—Metabolism—CYP2A6—prostate cancer	3.62e-06	4.05e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	3.62e-06	4.04e-05	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PPARA—prostate cancer	3.61e-06	4.03e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—ITPR1—prostate cancer	3.6e-06	4.02e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP2A6—prostate cancer	3.59e-06	4.01e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—COMT—prostate cancer	3.59e-06	4.01e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	3.58e-06	3.99e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GSTP1—prostate cancer	3.57e-06	3.99e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—SULT2A1—prostate cancer	3.57e-06	3.99e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—AKR1C3—prostate cancer	3.52e-06	3.94e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—ITPR1—prostate cancer	3.51e-06	3.93e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—MED12—prostate cancer	3.51e-06	3.92e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PRKACB—prostate cancer	3.5e-06	3.91e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—AKR1C3—prostate cancer	3.49e-06	3.9e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GNG5—prostate cancer	3.48e-06	3.89e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PRKACB—prostate cancer	3.47e-06	3.88e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP17A1—prostate cancer	3.47e-06	3.87e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—HSD3B1—prostate cancer	3.47e-06	3.87e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—SLC22A3—prostate cancer	3.47e-06	3.87e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP17A1—prostate cancer	3.44e-06	3.84e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—TYMS—prostate cancer	3.4e-06	3.79e-05	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CAV1—prostate cancer	3.39e-06	3.79e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	3.39e-06	3.79e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GSTM1—prostate cancer	3.36e-06	3.75e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—NCOA3—prostate cancer	3.35e-06	3.75e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTA4—prostate cancer	3.32e-06	3.71e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—TBXAS1—prostate cancer	3.32e-06	3.71e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—TYMS—prostate cancer	3.32e-06	3.71e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—NCOA2—prostate cancer	3.31e-06	3.69e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	3.3e-06	3.68e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—LPL—prostate cancer	3.3e-06	3.68e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GSTM1—prostate cancer	3.28e-06	3.67e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—NCOA2—prostate cancer	3.28e-06	3.66e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTA2—prostate cancer	3.24e-06	3.62e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—LPL—prostate cancer	3.22e-06	3.6e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—HPGDS—prostate cancer	3.2e-06	3.57e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—SULT1A1—prostate cancer	3.2e-06	3.57e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ABCG5—prostate cancer	3.2e-06	3.57e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CYP1A1—prostate cancer	3.18e-06	3.56e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP2C19—prostate cancer	3.18e-06	3.55e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—ERCC2—prostate cancer	3.16e-06	3.53e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—SLC5A5—prostate cancer	3.15e-06	3.52e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—SLC5A5—prostate cancer	3.13e-06	3.49e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTA1—prostate cancer	3.12e-06	3.49e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CYP1A1—prostate cancer	3.11e-06	3.48e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GSTT1—prostate cancer	3.1e-06	3.47e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—ACHE—prostate cancer	3.1e-06	3.47e-05	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PIK3CG—prostate cancer	3.09e-06	3.45e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTO1—prostate cancer	3.09e-06	3.45e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—NAT2—prostate cancer	3.09e-06	3.45e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—HSD3B2—prostate cancer	3.09e-06	3.45e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—ERCC2—prostate cancer	3.09e-06	3.45e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP2E1—prostate cancer	3.08e-06	3.44e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP2A6—prostate cancer	3.07e-06	3.43e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	3.06e-06	3.41e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP2E1—prostate cancer	3.05e-06	3.41e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—NQO1—prostate cancer	3.05e-06	3.4e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—NQO1—prostate cancer	3.02e-06	3.37e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—TH—prostate cancer	3e-06	3.35e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—AKR1C3—prostate cancer	2.98e-06	3.33e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—TH—prostate cancer	2.98e-06	3.32e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP3A4—prostate cancer	2.97e-06	3.32e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PRKACB—prostate cancer	2.97e-06	3.32e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—MTHFR—prostate cancer	2.97e-06	3.31e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—LRP2—prostate cancer	2.96e-06	3.31e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PLCB2—prostate cancer	2.96e-06	3.31e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP2C18—prostate cancer	2.96e-06	3.31e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.96e-06	3.3e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP3A4—prostate cancer	2.94e-06	3.29e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP17A1—prostate cancer	2.94e-06	3.28e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	2.93e-06	3.27e-05	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—INS—prostate cancer	2.93e-06	3.27e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP1B1—prostate cancer	2.92e-06	3.26e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PPARA—prostate cancer	2.91e-06	3.25e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—P4HB—prostate cancer	2.91e-06	3.24e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—MTHFR—prostate cancer	2.9e-06	3.24e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	2.9e-06	3.24e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP1B1—prostate cancer	2.89e-06	3.23e-05	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CREBBP—prostate cancer	2.87e-06	3.2e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PPARA—prostate cancer	2.85e-06	3.18e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GGT1—prostate cancer	2.83e-06	3.16e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—SLC22A1—prostate cancer	2.83e-06	3.16e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GGT1—prostate cancer	2.8e-06	3.13e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—NCOA2—prostate cancer	2.8e-06	3.13e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—NCOA1—prostate cancer	2.79e-06	3.11e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—NCOA1—prostate cancer	2.76e-06	3.08e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—SULT2A1—prostate cancer	2.75e-06	3.08e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP19A1—prostate cancer	2.75e-06	3.07e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CAV1—prostate cancer	2.74e-06	3.06e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP19A1—prostate cancer	2.72e-06	3.04e-05	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PIK3CD—prostate cancer	2.72e-06	3.03e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—MED12—prostate cancer	2.71e-06	3.03e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GNG5—prostate cancer	2.69e-06	3e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CAV1—prostate cancer	2.68e-06	2.99e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—SLC5A5—prostate cancer	2.67e-06	2.98e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—RXRA—prostate cancer	2.65e-06	2.96e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—RXRA—prostate cancer	2.63e-06	2.93e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP2E1—prostate cancer	2.61e-06	2.91e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—NCOA3—prostate cancer	2.59e-06	2.89e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—NQO1—prostate cancer	2.58e-06	2.88e-05	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—NOS3—prostate cancer	2.57e-06	2.87e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.55e-06	2.85e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—COMT—prostate cancer	2.55e-06	2.85e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—TH—prostate cancer	2.54e-06	2.84e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GSTP1—prostate cancer	2.54e-06	2.84e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—COMT—prostate cancer	2.53e-06	2.83e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.53e-06	2.82e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GSTP1—prostate cancer	2.52e-06	2.81e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP3A4—prostate cancer	2.52e-06	2.81e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	2.5e-06	2.8e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—ITPR1—prostate cancer	2.5e-06	2.79e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PIK3CG—prostate cancer	2.49e-06	2.78e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—ITPR1—prostate cancer	2.48e-06	2.77e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP1B1—prostate cancer	2.47e-06	2.76e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—HPGDS—prostate cancer	2.47e-06	2.76e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP2C19—prostate cancer	2.45e-06	2.74e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PIK3CG—prostate cancer	2.44e-06	2.72e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.44e-06	2.72e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTT1—prostate cancer	2.4e-06	2.68e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ACHE—prostate cancer	2.4e-06	2.68e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GGT1—prostate cancer	2.4e-06	2.68e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP2A6—prostate cancer	2.37e-06	2.64e-05	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PIK3CB—prostate cancer	2.37e-06	2.64e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—TYMS—prostate cancer	2.36e-06	2.64e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—INS—prostate cancer	2.36e-06	2.64e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—NCOA1—prostate cancer	2.36e-06	2.64e-05	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PTGS2—prostate cancer	2.35e-06	2.62e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—TYMS—prostate cancer	2.34e-06	2.61e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GSTM1—prostate cancer	2.33e-06	2.61e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP19A1—prostate cancer	2.33e-06	2.6e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GSTM1—prostate cancer	2.31e-06	2.58e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CREBBP—prostate cancer	2.31e-06	2.58e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—INS—prostate cancer	2.31e-06	2.58e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—AKR1C3—prostate cancer	2.3e-06	2.57e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PRKACB—prostate cancer	2.29e-06	2.56e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—LPL—prostate cancer	2.29e-06	2.56e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—LPL—prostate cancer	2.27e-06	2.54e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP17A1—prostate cancer	2.27e-06	2.53e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CREBBP—prostate cancer	2.26e-06	2.52e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—RXRA—prostate cancer	2.24e-06	2.51e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP1A1—prostate cancer	2.21e-06	2.47e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—ERCC2—prostate cancer	2.19e-06	2.45e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP1A1—prostate cancer	2.19e-06	2.45e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PIK3CD—prostate cancer	2.19e-06	2.45e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.18e-06	2.44e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—ERCC2—prostate cancer	2.18e-06	2.43e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—COMT—prostate cancer	2.16e-06	2.41e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—NCOA2—prostate cancer	2.16e-06	2.41e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GSTP1—prostate cancer	2.15e-06	2.4e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PIK3CD—prostate cancer	2.14e-06	2.39e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—ITPR1—prostate cancer	2.12e-06	2.36e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.08e-06	2.32e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—NOS3—prostate cancer	2.07e-06	2.31e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—MTHFR—prostate cancer	2.06e-06	2.3e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.06e-06	2.3e-05	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PTEN—prostate cancer	2.05e-06	2.29e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—MTHFR—prostate cancer	2.04e-06	2.28e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PPARA—prostate cancer	2.02e-06	2.26e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—NOS3—prostate cancer	2.02e-06	2.26e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.01e-06	2.25e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PPARA—prostate cancer	2.01e-06	2.24e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—TYMS—prostate cancer	2e-06	2.23e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—NQO1—prostate cancer	1.99e-06	2.22e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GSTM1—prostate cancer	1.98e-06	2.21e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—TH—prostate cancer	1.96e-06	2.19e-05	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—EP300—prostate cancer	1.95e-06	2.18e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—LPL—prostate cancer	1.94e-06	2.17e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PIK3CB—prostate cancer	1.91e-06	2.13e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.91e-06	2.13e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CAV1—prostate cancer	1.9e-06	2.12e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PTGS2—prostate cancer	1.89e-06	2.11e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CAV1—prostate cancer	1.89e-06	2.11e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP1A1—prostate cancer	1.87e-06	2.09e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PIK3CB—prostate cancer	1.87e-06	2.09e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—ERCC2—prostate cancer	1.86e-06	2.08e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PTGS2—prostate cancer	1.85e-06	2.07e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GGT1—prostate cancer	1.85e-06	2.06e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—NCOA1—prostate cancer	1.82e-06	2.03e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.8e-06	2.01e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.79e-06	2e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—MTHFR—prostate cancer	1.75e-06	1.95e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.73e-06	1.94e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—RXRA—prostate cancer	1.73e-06	1.93e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PIK3CG—prostate cancer	1.72e-06	1.92e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PPARA—prostate cancer	1.71e-06	1.91e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—COMT—prostate cancer	1.67e-06	1.86e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTP1—prostate cancer	1.66e-06	1.85e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PTEN—prostate cancer	1.65e-06	1.84e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—INS—prostate cancer	1.64e-06	1.83e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ITPR1—prostate cancer	1.63e-06	1.82e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—INS—prostate cancer	1.63e-06	1.82e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PTEN—prostate cancer	1.61e-06	1.8e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CAV1—prostate cancer	1.61e-06	1.8e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CREBBP—prostate cancer	1.61e-06	1.79e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CREBBP—prostate cancer	1.59e-06	1.78e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—EP300—prostate cancer	1.57e-06	1.76e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—TYMS—prostate cancer	1.54e-06	1.72e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.54e-06	1.72e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—EP300—prostate cancer	1.54e-06	1.72e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTM1—prostate cancer	1.53e-06	1.7e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.52e-06	1.7e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PIK3CD—prostate cancer	1.51e-06	1.69e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—LPL—prostate cancer	1.5e-06	1.67e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PIK3CG—prostate cancer	1.47e-06	1.64e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.45e-06	1.62e-05	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PIK3CA—prostate cancer	1.44e-06	1.61e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—NOS3—prostate cancer	1.44e-06	1.61e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ERCC2—prostate cancer	1.43e-06	1.6e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—NOS3—prostate cancer	1.43e-06	1.59e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—INS—prostate cancer	1.39e-06	1.55e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CREBBP—prostate cancer	1.36e-06	1.52e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—MTHFR—prostate cancer	1.35e-06	1.51e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.33e-06	1.48e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PPARA—prostate cancer	1.32e-06	1.48e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PIK3CB—prostate cancer	1.32e-06	1.47e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PTGS2—prostate cancer	1.32e-06	1.47e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PTGS2—prostate cancer	1.3e-06	1.46e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PIK3CD—prostate cancer	1.29e-06	1.44e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CAV1—prostate cancer	1.24e-06	1.39e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—NOS3—prostate cancer	1.22e-06	1.36e-05	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—AKT1—prostate cancer	1.18e-06	1.32e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PIK3CA—prostate cancer	1.16e-06	1.3e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PTEN—prostate cancer	1.15e-06	1.28e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PIK3CA—prostate cancer	1.14e-06	1.27e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PTEN—prostate cancer	1.14e-06	1.27e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.13e-06	1.27e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PIK3CB—prostate cancer	1.13e-06	1.26e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PTGS2—prostate cancer	1.11e-06	1.24e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—EP300—prostate cancer	1.09e-06	1.22e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—EP300—prostate cancer	1.08e-06	1.21e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—INS—prostate cancer	1.07e-06	1.2e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CREBBP—prostate cancer	1.05e-06	1.17e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PIK3CD—prostate cancer	9.96e-07	1.11e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PTEN—prostate cancer	9.72e-07	1.09e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—AKT1—prostate cancer	9.52e-07	1.06e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—NOS3—prostate cancer	9.41e-07	1.05e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—AKT1—prostate cancer	9.3e-07	1.04e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—EP300—prostate cancer	9.27e-07	1.04e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PIK3CB—prostate cancer	8.68e-07	9.7e-06	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PTGS2—prostate cancer	8.6e-07	9.61e-06	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PIK3CA—prostate cancer	8.1e-07	9.04e-06	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PIK3CA—prostate cancer	8.03e-07	8.96e-06	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PTEN—prostate cancer	7.5e-07	8.38e-06	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—EP300—prostate cancer	7.16e-07	7.99e-06	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PIK3CA—prostate cancer	6.86e-07	7.66e-06	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—AKT1—prostate cancer	6.61e-07	7.39e-06	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—AKT1—prostate cancer	6.56e-07	7.32e-06	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—AKT1—prostate cancer	5.6e-07	6.26e-06	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PIK3CA—prostate cancer	5.29e-07	5.91e-06	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—AKT1—prostate cancer	4.32e-07	4.83e-06	CbGpPWpGaD
